Abstract
Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant sideeffects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.
| Original language | English |
|---|---|
| Pages (from-to) | 7361-7365 |
| Number of pages | 5 |
| Journal | Anticancer Research |
| Volume | 34 |
| Issue number | 12 |
| Publication status | Published - Dec 1 2014 |
Keywords
- Neuroendocrine markers
- Predictive markers
- Renal cell carcinoma
- Sunitinib
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)